Using multiple statistical approaches, we have identified a set of novel biomarkers that may improve the ability of traditional AD biomarkers, Aβ42 and tau, to distinguish MCI/early-stage AD from cognitive normalcy and to predict the development of future cognitive impairment (i.e. detection of preclinical AD at increased risk of progression). The gene discussed is MAPT; the disease is Cognitive impairment.